Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cardio-vasculo-toxicity of carfilzomib | Number of patients with cardio-toxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of carfilzomib. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Systemic hypertension | Number of patients with as systemic hypertension | 6 months |
| Heart Failure Reduced Ejection Fraction | Number of patients with Heart Failure and Reduced Ejection Fraction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Prospective cohort of patients starting carfilzomib treatment.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mariana Mirabel | Contact | +33156095636 | mariana.mirabel@aphp.fr |
| Name | Affiliation | Role |
|---|---|---|
| Mariana Mirabel | Assistance Publique Hôpitaux de Paris - Université de Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Paris - Centre Université de Paris | Recruiting | Paris | 75015 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054219 | Neoplasms, Plasma Cell |
| D006333 | Heart Failure |
| D006973 | Hypertension |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Heart Failure Preserved Ejection Fraction | Number of patients with Heart Failure and Preserved Ejection Fraction | 6 months |
| Predictors of Cardiotoxicity | Correlation between cardio-vascular toxicity and patients' chacateristics. | 6 months |
| Impact on outcomes | Compare outcomes (mortality) in patients with cardiotoxicity and no cardiotoxicty. | 1 year |
| Safety | Compare outcomes (mortality) in patients with cardiotoxicity according to the continuation of carflzomib or its withdrawl. | 1 year |
| D014652 |
| Vascular Diseases |
| D064419 | Chemically-Induced Disorders |